Fibroblast Growth Factor

The FDA granted priority review to pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 fusions or rearrangements, according to a press release from the agent’s manufacturer.

There is an association between higher levels of fibroblast growth factor 23, or FGF23, and greater cardiovascular and mortality risks for adults with type 2 diabetes and normal or mildly impaired kidney function, according to findings published in Diabetes Care.

Incyte announced positive overall response rate and progression-free survival results for pemigatinib, a selective fibroblast growth factor receptor inhibitor under evaluation for patients who failed previous treatment for advanced or metastatic cholangiocarcinoma, according to a press release.